1. Introduction {#sec1}
===============

Stress-induced heart failure, also known as Broken Heart Syndrome or Takotsubo Syndrome, is a phenomenon first reported in 1990. Not an ischemic phenomenon, it is characterized by transient left ventricular (LV) apical akinesis with hypercontraction of the basal wall creating a ballooning appearance of the heart. It resembles the Japanese octopus trap giving it its moniker, Takotsubo. While previously believed to be a rare syndrome, the literature has a few larger volume series and registries that have been able to better characterize it, with evidence of a 19-fold increase in incidence between 2006 and 2012, suggesting that it is in fact underrecognized and more prevalent than previously understood \[[@B1]--[@B5]\]. While most commonly described in elderly, postmenopausal female patients with a strong association of neurologic or psychiatric disease, it has also been recognized in the postoperative patient. The hypothesized pathophysiology is a hyperadrenergic load that leads to a transient ventricular dyskinesis, unaccompanied by occlusive coronary artery disease (CAD) \[[@B3], [@B6], [@B7]\].

Clinical manifestations include ST elevation, depression, or T-wave changes, prolonged Qt interval, and mild increases in cardiac enzymes \[[@B3], [@B7]\]. Ninety percent of the time, complete resolution of apical wall motion abnormality and depressed LV systolic function occurs without an associated adverse event \[[@B7], [@B8]\]. While stress-induced heart failure is often self-limited and resolves with medical support alone, mechanical ventricular support is occasionally necessary to avoid death, especially in the presence of cardiogenic shock \[[@B9]\]. It is as deadly as an acute coronary syndrome with significant morbidity and mortality ranging from 5.8 to 27% and thus should be addressed with the same gravity \[[@B2], [@B7]\]. In a Swedish national registry, when Takotsubo is identified with physical triggers (as surgery), acute neurologic or psychiatric disease, an admission troponin measurement greater than 10 times the normal value, and an EF of less than 45%, an association for poor outcome was found \[[@B10]\]. As average survival after transplantation improves and centers, in fact, have increasing oversight in regard to their outcomes, the onus is on transplant centers to ensure maximal survival not only for the sake of the patients, but also for the sake of their transplant programs \[[@B11]\]. Furthermore, emerging evidence suggests that while the condition may be self-limiting the majority of times, 81.4% of in-house mortality with Takotsubo Syndrome was associated with underlying critical illness, like liver transplantation, and in this case, males were more susceptible than females \[[@B5], [@B12]\]. There are currently two evidence-based guidelines for the management of patients with Takotsubo, and, for severe cases, they mention the use of intra-aortic balloon pumps, left ventricular assist devices, and extracorporeal membrane oxygenation as a bridge to recovery \[[@B3], [@B13]\].

We describe our experience with stress-induced heart failure after orthotopic liver transplantation (OLT) and kidney transplantation in two transplant centers. Currently case reports and a few case series describe treatment of this entity with medical management or intra-aortic balloon pump (IABP). Furthermore, there is one study to describe the use of a LVAD to support Takotsubo cardiomyopathy \[[@B39]\] ([Table 1](#tab1){ref-type="table"}). We present the largest series yet, 7 surgical patients who suffered Takotsubo Syndrome after solid organ transplantation treated with three modalities: medical management, IABP, and mechanical flow support with a percutaneous ventricular assist device (pVAD). To our knowledge, this is the first to describe the successful use of a pVAD in the treatment of cardiogenic shock due to Takotsubo\'s Syndrome in liver transplant patients in the US.

2. Materials and Methods {#sec2}
========================

We performed a retrospective review of 2,303 liver and 734 kidney transplantations performed between two centers over 15 years (1998--2015) and identified 7 cases of posttransplant acute nonischemic heart failure. This required extensive review of paper charts up until the 2000s when electronic medical records occurred at both centers, after which electronic charts were mined. Then electronic records were reviewed up to 2015. Specifically, patient cardiac catheterizations were reviewed, both preoperatively and postoperatively, and review of postoperative echocardiographies was reviewed to assess for signs of acute changes and signs of Takotsubo Syndrome. Once that was identified, the case was reviewed in toto. All cases of nonischemic heart failure occurred within 7 days of transplantation, with the first case identified in 2009. Each case is characterized by patient demographics including gender, age, associated comorbidities, and diagnosis in addition to pre- and postoperative cardiac studies. We highlight these cases and detail the novel use of the TandemHeart™ pVAD (Houston, TX) in two of these cases.

2.1. Medical Management {#sec2.1}
-----------------------

Case 1 .A 45-year-old female with situs inversus, hypertension, hypothyroidism, and IgA nephropathy underwent living-related kidney transplantation. Preoperative transthoracic echocardiography (TTE) revealed preserved left ventricular ejection fraction (LVEF) of 55--60% but with impaired relaxation. Pulmonary arterial (PA) systolic pressures were 25--30 mmHg. Surgery was complicated by intraoperative hypotension requiring dopamine infusion as well as hypocalcemia secondary to intraoperative plasmapheresis, which was part of her immunosuppression induction protocol. She was extubated the same day. On postoperative day (POD) 2, she suffered a cardiac arrest after ventricular tachycardia, requiring 2 minutes of advanced cardiac life support (ACLS) and intubation. TTE revealed apical ballooning with severely decreased overall LV systolic function (LVEF 35%) consistent with Takotsubo Syndrome (TS). She maintained a normal serum creatinine of 0.8 mg/dL while being medically supported with vasopressors. By POD 4, the apical ballooning and the compromised EF were completely resolved. A repeat TTE on POD 6 showed normal systolic function (EF 55%, [Figure 1](#fig1){ref-type="fig"}) and normal chamber sizes. Cardiac catheterization was performed and proved no CAD. She was discharged on POD 9 and has since convalesced without further issue, with normal allograft function.

2.2. Intra-Aortic Balloon Pump {#sec2.2}
------------------------------

Case 2 .A 54-year-old man with hypertension, hyperlipidemia, subclinical hypothyroidism, and alcoholic cirrhosis (Model for End Stage Liver (MELD) score 37) underwent OLT. Preoperative echocardiography and a nuclear stress test revealed normal heart function without evidence of ischemia. There were no intraoperative complications. Overnight, he became hypotensive with atrial fibrillation with rapid ventricular response. He converted successfully to a sinus rhythm with amiodarone and vasopressin was started for hypotension. TTE showed mildly dilated ventricles bilaterally with severely decreased biventricular systolic function, (EF \< 20%) and trace mitral and tricuspid regurgitation, consistent with a Takotsubo Syndrome. Serial cardiac enzymes remained negative and his liver allograft continued to have normalizing liver function tests although he developed oliguric renal failure. Right and left heart catheterization confirmed poor ventricular function and no evidence of coronary disease and ischemia and an IABP was placed. Repeat TTE on POD 3 showed no significant change and continuous venovenous hemodialysis (CVVHD) was begun.

Echocardiogram POD 7 revealed no LV asymmetric wall motion abnormalities, mild-moderately dilated RV, and a moderate increase in systolic function (EF 30%); the IABP was removed. He was extubated on POD 9 and CVVHD was discontinued. On POD 20, TTE showed an EF of 25--35%, persistent global hypokinesis of LV, and elevated LV filling pressures. Beta blockade was begun; amiodarone was discontinued. The patient continued to improve and he was discharged on POD 30. Three months later, TTE showed an EF of 40% ([Figure 2](#fig2){ref-type="fig"}), normal LV filling pressures, and normal RV function. His liver allograft is functioning well.

Case 3 .A 34-year-old male with sleep apnea, hypertension, and alcoholic cirrhosis (MELD 36) underwent OLT. Preoperative TTE showed normal functions (EF 55--60%). His surgery involved a large blood loss and the perioperative course was significant for severe volume overload in the context of acute kidney injury. On POD 1, TTE revealed systolic dysfunction with EF of 25--29%, severe global LV hypokinesis, and elevated PA pressures. By POD 3, TTE showed EF of \<20%, severely decreased LV systolic function, severely enlarged right atrium, reduced RV systolic function, and severe mitral and tricuspid regurgitation. His midventricular wall motion abnormality was read as consistent with Takotsubo variant morphology. Systolic PA pressures were estimated at 50 mmHg. An IABP was placed POD 5, with milrinone and digoxin for inotropic support. The IABP was removed on POD 8 and, after inpatient rehabilitation, he was discharged on POD 22 with an EF of 30--34% and PAP 40--45 mmHg. Follow-up echocardiography continued to show compromised LV function with an EF ranging between 20 and 34%. This was exacerbated by difficulties with patient adherence to the medication regimen. Because EF never improved beyond 35% ([Figure 2](#fig2){ref-type="fig"}), a single-chamber ICD was placed 5 months postoperatively. His liver allograft is functioning well with normal liver function tests.

Case 4 .57-year-old male with hepatitis C (HCV) and alcoholic cirrhosis (MELD 36) underwent uneventful OLT. Preoperative echo showed mild atrial and RV dilation, with mild diastolic dysfunction and LVEF \> 60%; no preoperative cardiac catheterization was obtained. Intraoperative TEE was normal. On POD 1, he decompensated with hypoxia and dyspnea requiring intubation. TTE revealed EF of 10% ([Figure 2](#fig2){ref-type="fig"}) with global hypokinesis and cardiac catheterization revealed no significant CAD. An IABP was placed. Unfortunately, the patient passed from massive upper GI bleed while on a heparin infusion for IABP on POD 2.

*Patient 5.* A 46-year-old female with anxiety, depression, chronic renal insufficiency, and alcoholic cirrhosis (MELD 29) underwent OLT. She had a pacemaker for second-degree heart block and preoperative TTE revealed a mildly dilated left atrium with EF \> 55%. Intraoperatively, there was a brief episode of unexplained hypotension (\<5 minutes) with systolic pressures in the 50 s. After extubation on POD 2, she became tachypneic and oliguric, showing signs of heart failure. TTE revealed an EF of 15%, severe diastolic dysfunction, and akinesia of the apex with ballooning, basolateral-septal, mid, and apical-anterior wall segments in addition to severe tricuspid regurgitation and thus she was diagnosed with TS. An IABP was placed and supported the patient until removal on POD 10. TTE showed an improved EF at 30--35%, which was stable at 37% a week later ([Figure 2](#fig2){ref-type="fig"}). On POD 24, she was discharged in stable condition with a functioning liver allograft.

2.3. Percutaneous Ventricular Assist Device {#sec2.3}
-------------------------------------------

Case 6 .A 57-year-old male with HCV, hepatocellular carcinoma, alcoholic cirrhosis (MELD 26), and hepatopulmonary syndrome requiring home oxygen underwent an uneventful OLT. His heart history was significant only for a small asymptomatic patent foramen ovale. Preoperative TTE revealed a mildly dilated LV and left atrium with an EF of 60--65%. Pretransplant cardiac catheterization revealed no coronary lesions. He was extubated on POD 1 and progressed as expected until POD 7, when he became hypotensive with hypoxia and atrial fibrillation with rapid ventricular rate (RVR). TTE showed severe biventricular systolic dysfunction (EF \< 20%) and severe biatrial enlargement, consistent with Takotsubo Syndrome. Transesophageal echocardiogram confirmed global hypokinesis; there was no evidence of thrombus. Electrocardiograms revealed no ischemia along a vascular distribution but the patient was too unstable for a cardiac catheterization. Vasopressin was begun and multiple attempts at cardioversion failed. On POD 9, atrial fibrillation with RVR continued along with worsening hypoxia, increasing transaminases, and worsening coagulation profiles. Considering the extent of cardiogenic shock and allograft dysfunction, a pVAD (TandemHeart) was placed and CVVHD was started. Additionally, he underwent plasmapheresis and IVIG infusion for possible rejection and cytokine storm. Prior to removal of the pVAD on POD 22, TTE revealed a modest improvement in the EF to 30--35% and resolution of the global hypokinesis, although RV function was still poor. Over the next several days, the patient continued to experience intermittent episodes of unsustained atrial fibrillation and ventricular tachycardia which resolved with amiodarone and beta blockade. TTE on POD 32 showed normal LV size with EF of 40--44%.

He was discharged on POD 56 with normal liver function tests and coagulation profiles and improved renal function. Follow-up TTE after 3 months confirmed further improvement of EF to near his pretransplant baseline, 50--55% ([Figure 3](#fig3){ref-type="fig"}).

Case 7 .A 66-year-old male with autoimmune hemolytic anemia, chronic renal insufficiency, diabetes, hypertension, HCV, hepatocellular carcinoma, and alcoholic cirrhosis (MELD 23) underwent uneventful OLT. His cardiac history was significant for CAD for which he underwent coronary artery bypass 5 years earlier. Heart catheterization showed normal contractility with an occluded vein graft to a diagonal branch, but with retrograde filling. The distal LAD was occluded beyond the graft anastomosis. Preoperative TTE revealed normal LV function with EF of 55--60%. He was extubated on POD 1. On POD 3, he became hypotensive with hypoxia and acidosis in addition to having elevated transaminases. Echocardiography revealed LV apical ballooning with EF of 20--25%. On POD 4, coronary angiography revealed stable disease and a TandemHeart pVAD was inserted and his hypotension, acidosis, and hypoxia rapidly improved. Treatment was continued for 13 days with normalization of his liver enzymes. Prior to removal, TTE revealed a substantially improved EF of 50--55% and resolution of the apical akinesis ([Figure 3](#fig3){ref-type="fig"}). He was discharged on POD 58 and his allograft continues to function well.

3. Discussion {#sec3}
=============

We report the successful use of a pVAD in the treatment of 2 liver transplant cases of postoperative nonischemic, stress-induced heart failure. Contrary to primary Takotsubo Syndrome where treatment is focused solely on the heart, management of secondary Takotsubo Syndrome as in the posttransplant patients described here must include postoperative care in addition to immunosuppression. Although the syndrome is characteristically transient, mortality is estimated between 10 and 27% and is higher in those who present with cardiogenic shock. In the immediate setting, the syndrome can lead to major adverse cardiac and cerebrovascular events at 9.9% per patient-year, with a morbidity of 5.6% \[[@B1], [@B7]\]. Major adverse cardiac and cardiovascular sequelae of this entity include acute stroke, cardiogenic shock, arrhythmia, thrombus formation, left ventricular outflow tract obstruction, pericarditis with effusion, and ventricular wall rupture \[[@B3], [@B8], [@B16]--[@B18]\]. In the critical posttransplant period, failure to rescue can result in severe morbidity, including allograft compromise, and death. To date, a limited number of case reports have described the use of IABPs to augment cardiac output in post-OLT heart failure, and they are listed in [Table 1](#tab1){ref-type="table"}. Extracorporeal membrane oxygenation (ECMO) has been described on a few European case reports, and LVAD has been suggested as a rescue maneuver to support the low cardiac output as a bridge to recovery for high-risk Takotsubo, though not in transplant recipients \[[@B3], [@B13]\]. In our experience, a percutaneous VAD can be especially useful, and perhaps preferred, over the IABP after abdominal solid organ transplantation.

Our series is limited in that it is a retrospective review and dependent on review of copious paper and electronic charts with missing data, specifically data on pulmonary artery catheter measurements that helped to guide treatment. Having consistent data on pulmonary artery measurements would have strengthened the ability to inform treatment algorithms. Furthermore, 7 patients identified with posttransplant Takotsubo Syndrome are not many when culled from databases of over 3000 transplant patients. Our first patient was not identified until 2009, which suggests we may not have recognized this entity until later and it may be an underestimate of actual cases. This is consistent with a study that reviewed nationwide trends on TS between 2006 and 2012, and the reported incidence increased 19-fold during that time, perhaps related to improved recognition \[[@B5]\]. While the census is low, it may prove the point that failure to recognize this disease process means it is not as rare as previously believed and may in fact be more relevant to the transplant community. Assessing the role of exogenous catecholamines in this syndrome cannot be well-assessed in this series as our center\'s protocol mandates that all liver transplant recipients (if tolerated) receive empiric intraoperative dopamine infusions. Another limitation is that two of our patients did not have pre- or postoperative cardiac catheterizations, and while their echocardiograms, clinical courses, and biochemistries were convincing of the diagnosis of Takotsubo\'s Syndrome, it does not have the gold standard test to rule out an ischemic heart failure. It does bring up an important point, though, as in [Case 7](#casee7){ref-type="statement"}, that coexistence of coronary artery disease does not exclude Takotsubo\'s Syndrome \[[@B10]\].

All 7 of our patients had cardiogenic shock with biventricular failure and significant decreases in EF and cardiac function. One patient was treated with medical management, 4 were treated with IABPs ([Figure 4](#fig4){ref-type="fig"}), and 2 were treated with pVADs ([Figure 5](#fig5){ref-type="fig"}). In the 2 patients rescued with a pVAD, mechanical support was continued for 13--15 days with eventual recovery of cardiac function to near pretransplant levels, and, notably, without any loss in allograft function. Five of the six OLT patients improved during the course of their hospitalizations and were discharged home with varying degrees of cardiac improvement upon follow-up. [Case 4](#casee4){ref-type="statement"}, however, suffered death from GI bleeding due to the use of heparin infusion for the IABP on POD 2. This death brings up a salient limitation in the use of pVADs in the posttransplant and, in fact, postoperative patient. For all percutaneous assist devices, anticoagulation is necessary and indicated, and in the immediate postoperative setting, this presents a real limitation for the use of pVADs \[[@B19]\]. Most patients described had TS manifest within 48 hours of the perioperative period. However, if the patient has no evidence of bleeding and his cardiac shock leads to end organ dysfunction with benefits outweighing the risks, the utility of pVADs for treatment of Takotsubo\'s is evident.

It is noteworthy that the only patient who exhibited any shock liver was [Case 6](#casee6){ref-type="statement"}, who had his pVAD placed to support his hypoperfusion. While there is certainly no power in this study to support a causal relationship, the two patients who had a pVAD had near-complete resolution of their cardiac function ([Figure 3](#fig3){ref-type="fig"}) as compared to the four patients who had an IABP ([Figure 2](#fig2){ref-type="fig"}). This relationship deserves more study, especially considering the neutral data of the IABP-SHOCK II study \[[@B20]\]. The decision to use a pVAD over an IABP was because of the capabilities of our facilities and the fact that our patients were persistently unstable, with evidence of allograft dysfunction. Upon further review, IABP have been implicated in worsening the left ventricular outflow tract obstruction in Takotsubo\'s \[[@B3], [@B21], [@B22]\]. A European consensus study on Takotsubo\'s Syndrome recommended that if a patient with primary Takotsubo has cardiogenic shock with progressive multiorgan failure, it is prudent to consult for the use of ECMO or LVAD as a bridge to recovery \[[@B3], [@B23]\]. As it pertains to the case of secondary Takotsubo, as is for this series of cases, we have shown success with the use of percutaneous ventricular support. It is effective, minimally invasive, and temporary and requires no cardiopulmonary bypass. Nonetheless, the use of advanced mechanical circulatory support requires available expertise and carries its own set of risks including the potential need for a transseptal puncture and much larger sized cannulae for the vascular access.

In the context of altered vascular anatomy after liver or kidney transplantation, vascular compromise to the allograft and risks to the patient must be taken into special consideration when choosing a method of cardiac output augmentation. The pVAD is especially useful in conditions anticipated to be transient because of the ease of insertion and monitoring \[[@B24], [@B25]\]. Our one kidney transplant patient required medical support alone for resolution of her heart failure, but the theoretical benefits of pVAD over IABP would still apply for the unstable kidney transplant patient in cardiogenic shock. The pVAD avoids the need for cardiopulmonary bypass surgery for insertion and can be used for extended periods beyond those suggested for IABPs, making it ideal for patients in whom a major surgery is to be avoided \[[@B26]\]. Importantly, the use of IABP has been suggested to exacerbate mesenteric and renal ischemia by occlusion in a review of 106 patients, in a situation with already compromised perfusion, even with proper placement \[[@B27]\]. While the IABP augments diastolic perfusion in the descending aorta, the TandemHeart pVAD traverses the inferior vena cava (IVC) and terminates in the left atrium via a transseptal puncture ([Figure 4](#fig4){ref-type="fig"}). Its placement eliminates the potential occlusion of the celiac axis and supraceliac aorta; thus obstruction of the arterial vascular supply to the liver allograft is avoided with a pVAD ([Figure 5](#fig5){ref-type="fig"}). In the postoperative immunosuppressed LT patient, the risks to patient and graft are multiplied in cardiogenic shock \[[@B12]\]. Fortunately, if adequate cardiac support is provided in a timely manner, the patient can survive long enough for the condition to resolve.

Based on our experiences with liver transplant patients, a pVAD may serve as a life-saving bridge to cardiac recovery in the treatment of stress-induced heart failure. In our series of 7 surgical patients, we successfully used a TandemHeart pVAD to treat 2 cases of posttransplant cardiogenic shock. The pVAD provided a combination of ease of insertion and removal in the setting of severely compromised heart function. Its use may be anatomically and physiologically more forgiving to the new transplanted allograft in the setting of cardiogenic shock than IABPs as it avoids the potential of mesenteric aortic occlusion and yet allows for a longer duration of temporary support. In fact, IABPs are implicated in worsening left ventricular outflow obstruction, and recommendations against its use have emerged for Takotsubo Syndrome \[[@B13]\].

Review of the literature in combination with our experiences in liver transplant patients suggests that of those centers with the specialists and capabilities to allow for it, the pVAD may serve as a life-saving maneuver for cardiac and allograft recovery in the treatment of Takotsubo Syndrome within the transplant population. We believe the rarity but increasing incidence of this phenomenon dictates inclusion of all the modalities used at our centers and described in the literature, which allows the reader to understand the breadth of treatment modalities and outcomes available should their transplant patient be afflicted. It serves not only as a novel description of pVAD use in the transplant recipient, but also as an overview of treatment for mild to severe Takotsubo Syndrome all of which we have experienced at our centers amongst transplant patients, making it the largest series to date.
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![Ejection fraction with medical management after kidney transplant. Ejection fraction of [Case 1](#casee1){ref-type="statement"} from postoperative day (POD) 0 over time.](JTRANS2018-9739236.001){#fig1}

![Ejection fraction after intra-aortic balloon pump after OLT. Ejection fraction of Cases 2--5 from POD 0 over time. Dotted portion of each line marks time of intra-aortic balloon pump use.](JTRANS2018-9739236.002){#fig2}

![Ejection Fraction after percutaneous ventricular assist device after OLT. Ejection fraction of Cases 6 and 7 from POD 0 over time. Dotted portion of each line marks time of percutaneous ventricular assist device.](JTRANS2018-9739236.003){#fig3}

![Intra-aortic balloon pump after OLT for Takotsubo Syndrome. An intra-aortic balloon pump inserted in the right femoral artery, traversing the aorta as it passes the celiac axis, in the setting of Takotsubo Syndrome after an orthotopic liver transplantation. Typical arterial access cannula size 8 Fr (2.7 mm).](JTRANS2018-9739236.004){#fig4}

![Percutaneous mechanical assist device after OLT for Takotsubo Syndrome. A percutaneous mechanical assist device, inserted in the right femoral artery and vein, in the setting of Takotsubo Syndrome after orthotopic liver transplantation. Typical venous access cannula size 21 Fr (7 mm). Typical arterial access cannula size 15 Fr (5 mm).](JTRANS2018-9739236.005){#fig5}

###### 

\(a\) Literature review of Takotsubo Syndrome following abdominal transplant

  Authors                             \# of patients   Sex      Age                     Disease                                                                                      Organ transplanted                                   Management                                                                                                                                                       Outcome
  ----------------------------------- ---------------- -------- ----------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Anders et al. \[[@B32]\]            One              Male     66                      Laennec\'s cirrhosis                                                                         Liver                                                IABP on POD 2--23                                                                                                                                                Full recovery of cardiac function 40 days postop
  Bedanova et al. \[[@B14]\]          One              Female   51                      Autoimmune hepatitis and cirrhosis                                                           Liver                                                IABP on POD 2--9                                                                                                                                                 Full recovery of cardiac function 30 days postop
  Chrapko et al. \[[@B33]\]           One              Female   46                      Polycystic kidney disease                                                                    Kidney                                               Medical management. Diagnosed by TEE and ^123^I-mIBG myocardial uptake                                                                                           Full recovery of cardiac function by 180 days postop
  Eagle et al. \[[@B26]\]             One              Male     64                      Laennec\'s cirrhosis                                                                         Liver                                                RCA vasospasm found on cardiac catheterization, apical ballooning persisted. Transvenous pacemaker placed. Delayed biliary reconstruction to the following day   Small subdural hematoma treated medically. Discharged to rehabilitation facility on POD 16
  Gołębiewska et al. \[[@B34]\]       One              Female   68                      Glomerulonephritis                                                                           Kidney                                               Medical management. Possible association with Calcineurin Inhibitor Toxicity.                                                                                    Full recovery of cardiac function in 22 days post op
  Harika et al. \[[@B8]\]             One              Male     52                      Hemochromatosis and Laennec\'s cirrhosis                                                     Liver                                                Medical Management with vasopressors                                                                                                                             Full recovery of cardiac function in 18 days postop
  Lee et al. \[[@B30]\]               One              Female   65                      Nonalcoholic steatohepatitis with hepatocellular carcinoma                                   Liver                                                Medical management                                                                                                                                               Full recovery of cardiac function 6 weeks postop
  Phillips et al. \[[@B36]\]          One              Female   60                      Primary biliary cirrhosis, pulmonary embolus, renal failure, clostridium difficile colitis   Liver                                                Medical management with beta blockade and aspirin                                                                                                                Full recovery of cardiac function 16 days postop
  Saner et al. \[[@B31]\]             1/2              Male     60                      Hepatitis B cirrhosis                                                                        Liver                                                Medical Management with beta blockade.                                                                                                                           Recovery, doing well 4 years after transplant
  2/2                                 Female           62       Hepatitis C cirrhosis   Liver                                                                                        Medical management with vasopressors, hemodialysis   Death within 24 hours after transplant                                                                                                                           
  Tachotti Pires et al. \[[@B15]\]    1/2              Female   33                      Primary sclerosing cholangitis                                                               Liver                                                Medical management initially with vasopressors, then ACEI and beta blockade                                                                                      Recovery of EF on POD 10 though diagnosed with apical hypertrophic cardiomyopathy maintained on beta blockers
  2/2                                 Male             36       Budd-Chiari syndrome    Liver                                                                                        Medical management with vasopressors                 Recovery of cardiac function by POD 7 but found to have bacterial endocarditis, and expired 27 days postop                                                       
  Tiwari and D\'Attellis \[[@B37]\]   One              Female   45                      Nonalcoholic steatohepatitis                                                                 Liver                                                Medical management with vasopressors. Delayed biliary reconstruction to the following day. IABP POD 2--5                                                         Resolution in 12 days after transplant, though patient expired from hemorrhage
  Vailas et al. \[[@B38]\]            One              Male     51                      Trauma-inducing ESRD                                                                         Kidney                                               Medical management with vasopressors.                                                                                                                            Full recovery of cardiac function 4 days postop, but attempt at stenting RAS led to loss of allograft on POD 56
  Vachiat et al. \[[@B39]\]           One              Male     56                      Laennec\'s and HCV cirrhosis                                                                 Liver                                                Left ventricular assist device                                                                                                                                   Full recovery of cardiac function by POD 25

IABP: intra-aortic balloon pump; POD: postoperative day; TTE: transthoracic echocardiogram; RCA: right coronary artery; ACEI: ace inhibitor; EF: ejection fraction; RAS: renal artery stenosis.

###### 

\(b\) Case demographics, management, and outcomes summary

  Case                                      Sex      Age   Disease                                Organ transplanted   Management                Outcome
  ----------------------------------------- -------- ----- -------------------------------------- -------------------- ------------------------- -----------------------------------------------
  [Case 1](#casee1){ref-type="statement"}   Female   45    IgA nephropathy                        Kidney               Medical management        Full cardiac recovery POD 6
  [Case 2](#casee2){ref-type="statement"}   Male     54    Laennec\'s cirrhosis                   Liver                IABP                      Near-total recovery of heart function at 3 mo
  [Case 3](#casee3){ref-type="statement"}   Male     34    Laennec\'s cirrhosis                   Liver                IABP, ICD                 Partial recovery (EF 35%) at 5 mo
  [Case 4](#casee4){ref-type="statement"}   Male     57    Laennec\'s and Hepatitis C cirrhosis   Liver                IABP                      Death, POD2
  Case 5                                    Female   46    Laennec\'s cirrhosis                   Liver                IABP, ICD (preexisting)   Partial recovery (EF 35%) at 1 mo
  [Case 6](#casee6){ref-type="statement"}   Male     57    Laennec\'s and Hepatitis C cirrhosis   Liver                TandemHeart               Full cardiac recovery 3 mo
  [Case 7](#casee7){ref-type="statement"}   Male     66    Laennec\'s and Hepatitis C cirrhosis   Liver                TandemHeart               Full cardiac recovery 1 mo

IABP: intra-aortic balloon pump; POD: postoperative day; ICD: implantable cardioverter defibrillator; EF: ejection fraction.
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